Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...

The Trust has purchased the apartment on the 61st floor of Tower A, which is 17,384 sq ft big, according to documents ...

The Zydus Family Trust, associated with Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), a leading Indian ...

The Chan Zuckerberg Initiative (CZI) announced a new grand challenge to develop groundbreaking imaging technologies to transform how scientists observe, measure and understand living cells and ...

Zydus Lifesciences share price today, March 19: The share price of Zydus Lifesciences has risen by 1.8% in the past five trading sessions. (Image: Freepik) Zydus Lifesciences rose 3% to an intra ...

The recent approval enables Zydus Lifesciences to produce and sell Apalutamide Tablets, 60 mg (a generic equivalent of Erleada) in the United States. Apalutamide is an androgen receptor inhibitor ...

Zydus Lifesciences share price: Pharmaceutical company Zydus Lifesciences shares were buzzing in trade on Wednesday, March 19, 2025, as the scrip rose as much as 3.04 per cent to hit an intraday high ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week's approval for Eluxadoline tablets for IBS treatment. The stock shows a ...

Zydus Lifesciences, the Ahmedabad-based pharma giant, has started the intraday trade on Wednesday, March 19, on a positive note. This spurt in the share prices in the early session is a result of ...

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the ...

Zydus Lifesciences Limited announced on Tuesday that it has secured the final approval from the United States Food and Drug Administration (USFDA) for manufacturing and marketing apalutamide ...

Zydus Lifesciences share price extended the gains on third consecutive session on March 19, rising more than 1 percent after company received final approval from USFDA for Apalutamide Tablets ...